Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death in Asia and Africa (1). It reflects the high burden of hepatitis B virus (HBV) infection in these areas. Curative treatments of HCC as radiofrequency ablation and resection are impaired by a high rate of tumor recurrence. However, most of the time, HCC is frequently diagnosed at advanced stages where only palliative treatment as transarterial chemoembolization or sorafenib are recommended (1). Major advances have been performed in the field of molecular classification and identification of driver genes of liver carcinogenesis (2).